Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
TRAW
TRAW
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TRAW News
Traws Pharma Announces Clinical Results for Ratutrelvir with Promising Efficacy
Feb 19 2026
Newsfilter
Traws Pharma Advances Ratutrelvir COVID-19 Trial
Jan 26 2026
stocktwits
Traws Pharma Reports Clinical Progress on Ratutrelvir and Tivoxavir Marboxil
Jan 26 2026
Newsfilter
Plus Therapeutics Prices Public Offering, Raising $15 Million
Jan 15 2026
NASDAQ.COM
Traws Pharma's Oral COVID Treatment Demonstrates Results Similar to Paxlovid
Dec 17 2025
Benzinga
Traws Pharma's Ratutrelvir Shows Favorable Tolerability in COVID-19 Treatment
Dec 17 2025
Globenewswire
Traws Pharma's Ratutrelvir Shows Favorable Tolerability in COVID-19 Treatment
Dec 17 2025
Newsfilter
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Dec 15 2025
NASDAQ.COM
Linde Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Wednesday
Dec 03 2025
Benzinga
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
Oct 30 2025
PRnewswire
Dover, Delaware -- Expert Systems Inc. Backs Traws Pharma's Phase 2 Clinical Trials for Ratutrelvir, an Innovative Ritonavir-Free Antiviral Treatment for COVID-19.
Oct 22 2025
Newsfilter
Annovis Names Mark Guerin as CFO
Sep 24 2025
Globenewswire
Traws Pharma Granted Approval to Advance Phase 2 COVID Trials for Ratutrelvir, Anticipates Results by End of 2025
Aug 18 2025
Newsfilter
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
Jun 30 2025
Newsfilter
Traws Pharma Submits Phase 2 Protocols for Tivoxavir Marboxil and Ratutrelvir to HREC and FDA
Jun 30 2025
NASDAQ.COM
Traws Pharma advances antiviral pipeline with multiple regulatory submissions
Jun 30 2025
SeekingAlpha
Show More News
